Gemalto Brings Secure, Multi-Factor Authentication to Belgium’s Pioneering National Mobile Identity Scheme itsme®
5.6.2018 08:00:00 EEST | Business Wire | Press release
Gemalto (Euronext NL0000400653 GTO), the world leader in digital security, has enabled Belgian mobile ID scheme itsme® to enroll 350,000 users and securely process one million transactions per month for both private and public online services – making it one of the most successful mobile ID applications in Europe within one year of launch. As well as bringing greater convenience to consumers, itsme® provides merchants, government, and financial institutions with strong, multi-factor authentication that is in line with PSD2, GDPR and is certified for eIDAS.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180604006232/en/
Digital ID for Belgian citizens Credit: istockphoto
itsme® was developed by Belgian Mobile ID, a consortium of Belgium’s leading banks and mobile network operators, in close collaboration with Gemalto. It has been officially recognized by the Belgian government as a way for citizens to connect to numerous online public services, including taxation, pensions and health, as well as online banking and mobile operator services. In its first year the app is already being used widely, with the average user completing six banking transactions and three e-Government transactions each month.
In an increasingly digital world with growing numbers of government services moving online, a secure digital identity scheme allows consumers to prove who they are. The itsme® app allows users to create a 100% verifiable ID to safely and easily confirm their identity and approve transactions with their mobile phone, meaning they can access services on-the-go with one single login. The seamless service grants access to a wide portfolio of services, including those related to telecoms, financials, HR, and health, without having to fill in a time-consuming form each time. itsme® will also provide users in the near future with a qualified e-signature that is the legal equivalent of a handwritten signature, which they can use to easily sign documents.
Following many years of collaboration in the fields of banking and mobile payment security, Belgian Mobile ID tasked Gemalto with providing robust, end-to-end security for the itsme® app. Gemalto’s strong mobile authentication solution, using the latest biometric technology combined with digital identity expertise, provides the highest level of security for users to access services, confirm transactions and sign for private and government online applications. As a result, users stay in control of their data, managing privacy in a secure environment that protects them from fraud and security breaches.
Kris de Ryck, CEO, Belgian Mobile ID, commented, “The itsme® app is a significant milestone on the digital roadmap of Belgium and we could not have done it without Gemalto. Our partnership helps us provide a truly innovative and 100% secure approach to accessing online services. While Belgian citizens are leading the world in embracing technology in this Mobile Identity scheme, we hope our partnership will be an example for other countries in Europe to provide seamless and secure connections to online public services with itsme®.”
Philippe Vallée, CEO, Gemalto, added, “In an increasingly digital world the need for stronger and more trusted digital identities is growing. We know that consumers want their data to be secure, but they also want a painless and hassle-free experience when accessing online services. We hope that this is just the start and that further cooperation in this field will lead to more schemes providing a seamless online experience for everyone in Europe across many different sectors.”
Gemalto CEO Philippe Vallée and Kris De Ryck, CEO of Belgian Mobile ID, will be speaking on the topic of Digital identity at Money 20/20 in Amsterdam, on 5 June at 11.50am on the High Wire Stage.
In addition, stop by stand B50 to discover itsme® in action and to hear more about the latest innovations from Gemalto that can help your brand capitalize on existing and new technologies while ensuring simple, secure and enjoyable customer journeys.
About Gemalto
Gemalto (Euronext NL0000400653 GTO) is the global leader in digital security, with 2017 annual revenues of €3 billion and customers in over 180 countries. We bring trust to an increasingly connected world.
From secure software to biometrics and encryption, our technologies and services enable businesses and governments to authenticate identities and protect data so they stay safe and enable services in personal devices, connected objects, the cloud and in between.
Gemalto’s solutions are at the heart of modern life, from payment to enterprise security and the internet of things. We authenticate people, transactions and objects, encrypt data and create value for software – enabling our clients to deliver secure digital services for billions of individuals and things.
Our 15,000 employees operate out of 114 offices, 40 personalization and data centers, and 35 research and software development centers located in 47 countries.
For more information visit www.gemalto.com, or follow @gemalto on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180604006232/en/
Contact information
Gemalto media:
Tauri Cox, +1 512 257 3916
North America
tauri.cox@gemalto.com
or
Sophie
Dombres, +33 4 42 36 57 38
Europe Middle East & Africa
or
sophie.dombres@gemalto.com
Jaslin
Huang, +65 6317 3005
Asia Pacific
jaslin.huang@gemalto.com
or
Enriqueta
Sedano, +52 5521221422
Latin America
enriqueta.sedano@gemalto.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
